HyFoSy Versus HSG as a Diagnostic Technique for Tubal Patency.
HyFoSy Versus HSG as a Diagnostic Technique for Tubal Patency: a Prospective Case-control Study.
Observational, single-center, prospective case-control study, in which each patient is his own control.
It focuses on the study of tubal patency and establishing the agreement of results between HyFoSy and HSG.
Study Overview
Status
Status
Conditions
Conditions
Detailed Description
Observational, single-center, case-control study in which tubal pathology is studied in the context of a Basic Sterility Study.
The main objective of this study is to demonstrate the concordance of this new diagnostic test (HyFoSy) with HSG, which is the common technique to visualize tubal patency. Once demonstrated concordance, we also want to carry out a cost-effectiveness study and demonstrate through different scales the greater ease of the test, less time to perform and less pain for the patient.
It is a study in which the patients are women between 18-39 years old, undergoing study for primary sterility, with a BMI <30, AMH> 0.6 (good ovarian reserve).
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Contacts and Locations
Study Locations
-
-
-
Sevilla, Spain, 41009
- Hospital Universitario Virgen Macarena
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Women between 18-39 years, under study for primary sterility, with BMI <30, AMH> 0.6 (good ovarian reserve), subsidiaries of Conjugal or Donor IA, according to the 2019 SAS Reproduction Guide.
Exclusion Criteria:
- Women <19 or> 39 years old, BMI> 30, secondary sterility, previous tubal sterilization, that is, the ART exclusion criteria according to the 2019 SAS Reproduction Guide.
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
|---|
|
Cases-Control
Women aged 18-39 years, with BMI <30 and good ovarian reserve, undergoing study for primary sterility, subsidiary of conducting tubal patency studies to rule out pathology of the same and thus be able to perform Spousal or Donor IA.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Study of tubal patency and establish the concordance of results between HyFoSy and HSG.
Time Frame: Up to 48 weeks.
|
Concordance study between HyFoSy and HSG.
It is a qualitative study (yes / no).
|
Up to 48 weeks.
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Rate of occurrence of complications in the patients included in the study.
Time Frame: Up to 48 weeks.
|
Expand the knowledge of the complications in the clinical practice of HyFoSy, confirming the lower perception of pain and the therapeutic effect of HyFoSy.
|
Up to 48 weeks.
|
|
Time costs of performing HyFoSy versus HSG.
Time Frame: Up to 48 weeks.
|
Compare the time it takes to see the effect of the study drug compared to HSG.
|
Up to 48 weeks.
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Angela Morales Bueno, Hospital Universitario Virgen Macarena
Study record dates
Study Major Dates
Study Start (ACTUAL)
Study Start
Primary Completion (ANTICIPATED)
Primary Completion
Study Completion (ANTICIPATED)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (ACTUAL)
First Posted
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- FIS-HyF
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Sterility
-
NCT06795568Not yet recruitingInfertility, Sterility, Reproductive, Reproductive Sterility, Sterility, Subfertility, Sub-Fertility
-
NCT04809428CompletedSterility, Female
-
NCT01331720Completed
-
NCT02050672Completed
-
NCT01376999CompletedNo Explained Sterility
-
NCT03429621CompletedSterility, Postpartum
-
NCT02522806Completed
-
NCT01292850CompletedSkin Sterility After Use of Ethyl-chloride Spray.
-
NCT03438682CompletedContraception | Sterility, Female | Contraceptive Device; Complications